CN102421779A - 二氢喋啶酮类衍生物、其制备方法及其在医药上的应用 - Google Patents

二氢喋啶酮类衍生物、其制备方法及其在医药上的应用 Download PDF

Info

Publication number
CN102421779A
CN102421779A CN2011800020673A CN201180002067A CN102421779A CN 102421779 A CN102421779 A CN 102421779A CN 2011800020673 A CN2011800020673 A CN 2011800020673A CN 201180002067 A CN201180002067 A CN 201180002067A CN 102421779 A CN102421779 A CN 102421779A
Authority
CN
China
Prior art keywords
protective embankment
embankment base
heterocyclic radical
base
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN2011800020673A
Other languages
English (en)
Other versions
CN102421779B (zh
Inventor
邓炳初
张农
董正
曾祥全
舒思杰
刘伦俊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Hengrui Medicine Co Ltd
Shanghai Hengrui Pharmaceutical Co Ltd
Shanghai Shengdi Pharmaceutical Co Ltd
Original Assignee
Jiangsu Hengrui Medicine Co Ltd
Shanghai Hengrui Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd filed Critical Jiangsu Hengrui Medicine Co Ltd
Priority to CN201180002067.3A priority Critical patent/CN102421779B/zh
Publication of CN102421779A publication Critical patent/CN102421779A/zh
Application granted granted Critical
Publication of CN102421779B publication Critical patent/CN102421779B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明涉及二氢喋啶酮类衍生物、其制备方法及其在医药上的应用。具体而言，本发明涉及一种通式(I)所示的新的二氢喋啶酮类衍生物、其制备方法及含有该衍生物的药物组合物以及其作为治疗剂特别是作为Plk激酶抑制剂的用途，其中通式(I)的各取代基与说明书中的定义相同。

Description

PCT国内申请，说明书已公开。

Claims (1)

  1. PCT国内申请，权利要求书已公开。
CN201180002067.3A 2010-03-19 2011-01-14 二氢喋啶酮类衍生物、其制备方法及其在医药上的应用 Expired - Fee Related CN102421779B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201180002067.3A CN102421779B (zh) 2010-03-19 2011-01-14 二氢喋啶酮类衍生物、其制备方法及其在医药上的应用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201010131438.5 2010-03-19
CN2010101314385 2010-03-19
CN2010101314385A CN102190669A (zh) 2010-03-19 2010-03-19 二氢喋啶酮类衍生物、其制备方法及其在医药上的应用
CN201180002067.3A CN102421779B (zh) 2010-03-19 2011-01-14 二氢喋啶酮类衍生物、其制备方法及其在医药上的应用
PCT/CN2011/000062 WO2011113293A1 (zh) 2010-03-19 2011-01-14 二氢喋啶酮类衍生物、其制备方法及其在医药上的应用

Publications (2)

Publication Number Publication Date
CN102421779A true CN102421779A (zh) 2012-04-18
CN102421779B CN102421779B (zh) 2015-03-11

Family

ID=44599624

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2010101314385A Pending CN102190669A (zh) 2010-03-19 2010-03-19 二氢喋啶酮类衍生物、其制备方法及其在医药上的应用
CN201180002067.3A Expired - Fee Related CN102421779B (zh) 2010-03-19 2011-01-14 二氢喋啶酮类衍生物、其制备方法及其在医药上的应用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN2010101314385A Pending CN102190669A (zh) 2010-03-19 2010-03-19 二氢喋啶酮类衍生物、其制备方法及其在医药上的应用

Country Status (2)

Country Link
CN (2) CN102190669A (zh)
WO (1) WO2011113293A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114276349A (zh) * 2021-12-13 2022-04-05 复旦大学 2-氨基喋啶酮类衍生物或其盐及其制备方法和用途

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102017005089A1 (de) 2016-05-30 2017-11-30 Bayer Pharma Aktiengesellschaft Substitulerte 3,4-Dihydrochinoxalin-2(1H)-one
DE102017005091A1 (de) 2016-05-30 2017-11-30 Bayer Pharma Aktiengesellschaft Substituierte 3,4-Dihydropyrido[2,3-b]pyrazin-2(1H)-one

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1745081A (zh) * 2003-02-26 2006-03-08 贝林格尔英格海姆法玛两合公司 二氢蝶啶酮、其制法及作为药物制剂的用途
CN101039676A (zh) * 2004-08-14 2007-09-19 贝林格尔·英格海姆国际有限公司 具有长贮存期的二氢蝶啶酮的输注溶液
CN101541800A (zh) * 2006-10-25 2009-09-23 色品疗法有限公司 用于治疗癌症的作为plk抑制剂的蝶啶衍生物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1745081A (zh) * 2003-02-26 2006-03-08 贝林格尔英格海姆法玛两合公司 二氢蝶啶酮、其制法及作为药物制剂的用途
CN101039676A (zh) * 2004-08-14 2007-09-19 贝林格尔·英格海姆国际有限公司 具有长贮存期的二氢蝶啶酮的输注溶液
CN101541800A (zh) * 2006-10-25 2009-09-23 色品疗法有限公司 用于治疗癌症的作为plk抑制剂的蝶啶衍生物

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114276349A (zh) * 2021-12-13 2022-04-05 复旦大学 2-氨基喋啶酮类衍生物或其盐及其制备方法和用途
CN114276349B (zh) * 2021-12-13 2024-04-09 复旦大学 2-氨基喋啶酮类衍生物或其盐及其制备方法和用途

Also Published As

Publication number Publication date
CN102190669A (zh) 2011-09-21
WO2011113293A1 (zh) 2011-09-22
CN102421779B (zh) 2015-03-11

Similar Documents

Publication Publication Date Title
CN115192577B (zh) Kras突变蛋白抑制剂
KR102493364B1 (ko) Menin-mll 상호작용의 융합 바이사이클릭 억제제
RU2708674C2 (ru) Конденсированные кольцевые гетероарильные соединения и их применение в качестве ингибиторов trk
JP7008064B2 (ja) Ｆｇｆｒ４阻害剤としてのヘテロ環式化合物
ES2951427T3 (es) Macrociclo que contiene aminopirazol y pirimidina y composición farmacéutica y uso del mismo
CN103547577B (zh) 作为盐皮质激素受体拮抗剂的并环类化合物
CN102421778A (zh) 二氢喋啶酮类衍生物、其制备方法及其在医药上的应用
DE602004003952T2 (de) Substituierte tetrahydrobenzothienopyrimidinamine verbindungen geeignet zur behandlung von hyper-proliferative disorders
BR112020026653A2 (pt) Compostos heterocíclicos como inibidores de trk
CA2940918A1 (en) Substituted 4,5,6,7-tetrahydro-pyrazolo[1,5-.alpha.]pyrazine derivatives and 5,6,7,8-tetrahydro-4h-pyrazolo[1,5-.alpha.][1,4]diazepine derivatives as ros1 inhibitors
CA3186981A1 (en) Phthalazinone compound, and preparation method therefor and medical use thereof
KR102556482B1 (ko) 테트라히드로이소퀴놀린계 화합물, 이의 제조 방법, 테트라히드로이소퀴놀린계 화합물을 포함하는 약물 조성물 및 이의 용도
WO2019173613A1 (en) Substituted fused pyrrolo-diazepinones and uses thereof
CN111171019A (zh) 一类五元并六元杂环化合物及其作为蛋白受体激酶抑制剂的用途
EP4037677A1 (en) Antagonists of the muscarinic acetylcholine receptor m4
ES2850023T3 (es) Compuesto de anillo heterocíclico nítrico de seis miembros sustituido con amino y preparación y uso del mismo
CN102421779A (zh) 二氢喋啶酮类衍生物、其制备方法及其在医药上的应用
CN107848971A (zh) 杂环化合物
CN104936944B (zh) 作为酪氨酸激酶抑制剂的吲哚满酮衍生物
EP4055013B1 (en) Wdr5 inhibitors and modulators
CN102675290B (zh) 含有并环的二氢吡唑类化合物
CN102491929B (zh) 1-羟基-2-吡咯烷酮类化合物及其制备方法和应用
RU2792034C2 (ru) Тетрагидроизохинолиновое соединение, способ его получения, фармацевтическая композиция, содержащая такое соединение, и его применение
RU2779497C2 (ru) Макроцикл, содержащий аминопиразол и пиримидин, и его фармацевтическая композиция и применение
CN103492371A (zh) 含有螺环的二氢吡唑类化合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20180518

Address after: 222047 No. 7 Kunlun Shan Road, Lianyungang economic and Technological Development Zone, Jiangsu

Co-patentee after: SHANGHAI HENGRUI PHARMACEUTICAL Co.,Ltd.

Patentee after: JIANGSU HENGRUI MEDICINE Co.,Ltd.

Co-patentee after: SHANGHAI SHENGDI PHARMACEUTICAL Co.,Ltd.

Address before: 222047 No. 7 Kunlun Shan Road, Lianyungang economic and Technological Development Zone, Jiangsu

Co-patentee before: SHANGHAI HENGRUI PHARMACEUTICAL Co.,Ltd.

Patentee before: JIANGSU HENGRUI MEDICINE Co.,Ltd.

TR01 Transfer of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20150311

Termination date: 20220114

CF01 Termination of patent right due to non-payment of annual fee